What is Sun Pharma's new skin cancer drug called?

Sun Pharma's new skin cancer drug is called Unloxcyt (cosibelimab-ipdl).

Which type of skin cancer does Unloxcyt treat?

Unloxcyt treats advanced metastatic and locally advanced cutaneous squamous cell carcinoma (mCSCC/llaCSCC).

Who is eligible to receive Unloxcyt in the US?

Adult patients with advanced mCSCC or llaCSCC not candidates for curative surgery or radiation are eligible.

Home / Business and Economy / Sun Pharma Launches Skin Cancer Drug in US

Sun Pharma Launches Skin Cancer Drug in US

16 Jan

•

Summary

Sun Pharma has launched its skin cancer drug, Unloxcyt, in the United States.
The drug treats advanced forms of cutaneous squamous cell carcinoma.
An estimated 40,000 US patients annually progress to advanced skin cancer disease.

Sun Pharma Launches Skin Cancer Drug in US

Sun Pharmaceutical Industries has officially launched its novel skin cancer medication, Unloxcyt (cosibelimab-ipdl), in the United States market as of January 16, 2026. This groundbreaking drug is now accessible for healthcare professionals to prescribe to adult patients suffering from metastatic or locally advanced cutaneous squamous cell carcinoma.

The treatment is specifically indicated for patients who have progressed to advanced stages of the disease and are not eligible for curative surgical or radiation therapies. Unloxcyt represents a significant advancement in checkpoint inhibition, aiming to provide both lasting efficacy and a manageable tolerability profile for this vulnerable patient group.